Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck

Journal of Clinical Oncology

Volumn 24, Issue 25, 2006, Pages 4163-4169

  Tsao, Anne S ^a   Garden, Adam S ^a   Kies, Merrill S ^a   Morrison, William ^a   Feng, Lei ^a   Lee, J Jack ^a   Khuri, Fadlo ^a   Zinner, Ralph ^a   Myers, Jeffery ^a   Papadimitrakopoulou, Vassiliki ^a   Lewin, Jan ^a   Clayman, Gary L ^a   Ang, K Kian ^a   Glisson, Bonnie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DOSE RESPONSE; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; SQUAMOUS CELL CARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; HEAD AND NECK TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; RADIATION DOSE FRACTIONATION; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33748636873     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.7851     Document Type: Article

References (22)

1. Withers HR, Taylor JM, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131-146, 2001
2. Garden AS: Altered fractionation for head and neck cancer. Oncology (Williston Park) 15:1326-1332, 2001: discussion 15:1339-1341, 2001
3. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
4. Bourhis J, Amand C, Pignon J-P, et al: Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 23:489s, 2005 (suppl; abstr 5505)
5. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
6. Brizel DM, Albers ME, Fishers SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
7. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999
8. Glisson BS: The role of docetaxel in the management of squamous cell cancer of the head and neck. Seminars in Oncol 16s:83-87, 2002
9. Milas L, Mason KA, Liao Z, et al: Chemoradiotherapy: Emerging treatment improvement strategies. Head Neck 25:152-167, 2003
10. Mauer AM, Masters GA, Haraf DJ, et al: Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16:159-164, 1998
11. Tishler RB, Norris CM Jr, Colevas AD, et al: A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 95:1472-1481, 2002
12. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
13. Brookmeyer R: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
14. Garden AS, Glisson BS, Ang KK, et al: Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: Toxicities and responses. J Clin Oncol 17:2390-2395, 1999
15. Staar S, Rudat V, Stuetzer H, et al: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:1161-1171, 2001
16. Garden AS, Harris J, Vokes EE, et al: Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22:2856-2864, 2004
17. Calais G, Bardet E, Sire C, et al: Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma: Results of the 98-02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys 58:161-166, 2004
18. Ang KK, Harris J, Garden AS, et al: Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol 23:3008-3015, 2005
19. Inohara H, Inoue T, Akahani S, et al: Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer: A phase I study. Anticancer Res 24:4135-4140, 2004
20. Schwartz D, Montgomery R, Yueh B, et al: Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 103:2535-2543, 2005
21. Katori H, Tsukuda M, Mochimatu I, et al: Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90:348-352, 2004
22. Denis F, Garaud P, Bardet E, et al: Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55:93-98, 2003